---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000064"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:26:19.520086+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%

## Summary
- Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).
- Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).
- CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.
- Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call.

## SEC filing metadata
- accession: 0001770787-24-000064
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/0001770787-24-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/txg-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000064
- JSON: https://secwatch.observer/filing/0001770787-24-000064.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.